Get the Stockscreener App
4.67
3.32%
0.15
After Hours:
4.67
Curevac N V stock is traded at $4.67, with a volume of 1.55M.
It is up +3.32% in the last 24 hours and down -8.61% over the past month.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
See More
Previous Close:
$4.52
Open:
$4.52
24h Volume:
1.55M
Relative Volume:
1.45
Market Cap:
$1.05B
Revenue:
$596.48M
Net Income/Loss:
$123.72M
P/E Ratio:
8.5157
EPS:
0.5484
Net Cash Flow:
$106.59M
1W Performance:
+8.60%
1M Performance:
-8.61%
6M Performance:
-13.52%
1Y Performance:
+35.36%
1-Day Range:
$4.48
$4.68
1-Week Range:
$4.255
$4.68
52-Week Range:
$2.475
$5.72
Curevac N V Stock (CVAC) Company Profile
Compare CVAC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVAC
Curevac N V
|
4.67 | 1.02B | 596.48M | 123.72M | 106.59M | 0.5484 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Curevac N V Stock (CVAC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-13-25 | Downgrade | Jefferies | Buy → Hold |
| Apr-25-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-08-23 | Initiated | SVB Securities | Outperform |
| Jan-19-23 | Upgrade | UBS | Neutral → Buy |
| Jan-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jan-21-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-18-22 | Initiated | JMP Securities | Mkt Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Hold |
| Jun-17-21 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-26-21 | Resumed | Credit Suisse | Underperform |
| Apr-26-21 | Initiated | Guggenheim | Neutral |
| Dec-10-20 | Downgrade | Credit Suisse | Neutral → Underperform |
| Sep-08-20 | Initiated | BofA Securities | Buy |
| Sep-08-20 | Initiated | Credit Suisse | Neutral |
| Sep-08-20 | Initiated | Jefferies | Hold |
View All
Curevac N V Stock (CVAC) Latest News
CureVac Shareholders Approve BioNTech Exchange Offer - MSN
CureVac NV’s CVAC Stock: Volatile Gene?Therapy Bet Faces Tough Crowd On Wall Street - AD HOC NEWS
How CureVac N.V. stock reacts to Fed rate cutsVolatility Adjusted Trading & Free Navigate Market Confidently - bollywoodhelpline.com
CureVac (NASDAQ:CVAC) Reaches New 12-Month HighWhat's Next? - MarketBeat
BioNTech Consolidates mRNA Leadership with CureVac Acquisition Finalization - AD HOC NEWS
Fundamentals Check: so 6 y nghia la giInsider Buying & Low Risk High Win Rate Stock Picks - moha.gov.vn
A New Chapter Begins: BioNTech Completes CureVac Acquisition - AD HOC NEWS
BioNTech Consolidates mRNA Leadership with CureVac Acquisition Finalized - AD HOC NEWS
BioNTech SE (BNTX) Closes the Acquisition of CureVac N.V. - Finviz
CureVac’s Final Chapter: BioNTech Acquisition Paves Way for Delisting - AD HOC NEWS
CureVac (NASDAQ:CVAC) Hits New 12-Month LowHere's Why - MarketBeat
CureVac’s Independent Trading Journey Concludes with BioNTech Acquisition - AD HOC NEWS
BioNTech Sharpens Strategic Focus with mRNA Oncology Push - AD HOC NEWS
BioNTech Secures CureVac Acquisition, Finalizes European mRNA Leadership - AD HOC NEWS
Should I hold or sell CureVac N.V. stock in 20252025 Major Catalysts & High Accuracy Swing Entry Alerts - Улправда
Can CureVac N.V. stock surprise with earnings upsideJuly 2025 Sector Moves & Verified Chart Pattern Trade Signals - Улправда
Will CureVac N.V. stock remain a Wall Street favoriteWeekly Investment Summary & Daily Momentum Trading Reports - Улправда
How buybacks impact CureVac N.V. stock valueEntry Point & Fast Gaining Stock Strategy Reports - Улправда
How institutional buying supports CureVac N.V. stockJuly 2025 Snapshot & AI Powered Market Entry Ideas - Улправда
CureVac (NASDAQ:CVAC) Shares Gap DownTime to Sell? - MarketBeat
How CureVac N.V. stock responds to policy changes2025 Market Sentiment & Safe Investment Capital Preservation Plans - DonanımHaber
Will CureVac N.V. stock benefit from infrastructure spendingWeekly Trend Summary & Precise Swing Trade Alerts - DonanımHaber
Sentiment Recap: Will CureVac N.V. stock benefit from infrastructure spendingJuly 2025 Highlights & Daily Price Action Insights - DonanımHaber
Can CureVac N.V. stock deliver consistent earnings growthJuly 2025 Outlook & Verified Swing Trading Watchlists - DonanımHaber
BioNTech’s CureVac Acquisition: A Test of Strategic Execution - AD HOC NEWS
EPS Watch: Will CureVac N.V. stock rally after Fed decisionsSwing Trade & Long-Term Growth Stock Strategies - Улправда
BioNTech Shareholders Await Integration Payoff After CureVac Acquisition - AD HOC NEWS
BioNTech Completes CureVac Acquisition to Bolster mRNA Leadership - TipRanks
BioNTech completes CureVac acquisition to bolster mRNA leadership - MSN
CureVac (CVAC) investors tender 195.3M shares as BioNTech plans delisting - Stock Titan
BioNTech (BNTX) closes CureVac N.V. exchange offer to bolster mRNA position - Stock Titan
Will CureVac N.V. stock rally after Fed decisionsTrade Risk Report & Proven Capital Preservation Tips - Улправда
BioNTech : Publishes Final Results of the Exchange Offer for CureVac - marketscreener.com
BioNTech Closes CureVac Acquisition - marketscreener.com
BioNTech Closes Acquisition Of CureVac N.V. Including Subsequent Offering Period To Strengthen Its Unique Position In The MRNA Field >BNTX - 富途牛牛
BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field - The Manila Times
Biontech closes acquisition of CureVac - marketscreener.com
BioNTech Completes Acquisition of CureVac with 86.75% Share Tendered - Quiver Quantitative
Two early mRNA firms join forces as BioNTech buys CureVac - Stock Titan
CureVac N.V.(NasdaqGM: CVAC) dropped from S&P Global BMI Index - marketscreener.com
CureVac (NASDAQ:CVAC) Trading Down 9.9%Time to Sell? - MarketBeat
CureVac N.V. (NASDAQ:CVAC) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
BioNTech Shares Gain Momentum from Acquisition and Clinical Progress - AD HOC NEWS
CureVac Enters Oversold Territory (CVAC) - Nasdaq
CureVac's Trading Era Concludes as BioNTech Merger Takes Hold () - aktiencheck.de
BIONTECH : Berenberg keeps its Buy rating - marketscreener.com
BioNTech's Oncology Pipeline Gains Momentum with Key Clinical Data () - aktiencheck.de
Trading Recap: Chien thuat ca cuoc dai han de kiem tienQuarterly Earnings Summary & Daily Growth Stock Tips - BỘ NỘI VỤ
CureVac Acquisition Finalized as BioNTech Secures Controlling Stake () - aktiencheck.de
CureVac Valuation After 2025 Rebound and DCF Suggests Large Gap to Fair Value - Yahoo Finance
Can CureVac N.V. stock reach $100 price targetWeekly Trade Analysis & Free Risk Controlled Daily Trade Plans - Newser
Curevac N V Stock (CVAC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):